🟢 Haemonetics is trading 10.22% up in pre-market after disclosing CSL Plasma supply agreement

Haemonetics is trading 10.22% up at $99.50 after disclosing a non-exclusive U.S. supply agreement with CSL Plasma on August 18, 2026.

• The agreement covers NexSys PCS systems with Persona PLUS technology and related disposables.
• CSL is expected to transition some collection centers.
• Haemonetics has not updated fiscal 2027 guidance; financial details are expected during the November 2026 earnings call.